You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxybutynin
Accession NumberDB01062  (APRD00427)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionOxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.
Structure
Thumb
Synonyms
4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester
4-Diethylamino-2-butinyl alpha-cyclohexylmandelat
4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate
Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester
Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester
Oxibutinina
Oxybutynin
Oxybutynine
Oxybutyninum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Albert Oxybutynintablet5 mgoralAventis Pharma Inc1996-11-212002-07-29Canada
Ava-oxybutynintablet5 mgoralAvanstra Inc2011-08-222014-08-21Canada
Ditropan Syrup 1mg/mlsyrup1 mgoralJanssen Inc1993-12-312007-02-21Canada
Ditropan Tablets 5mgtablet5 mgoralJanssen Inc1993-12-312006-08-04Canada
Ditropan XLtablet, extended release15 mg/1oralJanssen Pharmaceuticals, Inc.1999-06-26Not applicableUs
Ditropan XLtablet, extended release10 mg/1oralPhysicians Total Care, Inc.2003-06-23Not applicableUs
Ditropan XLtablet, extended release15 mg/1oralPhysicians Total Care, Inc.2003-06-25Not applicableUs
Ditropan XLtablet, extended release5 mg/1oralJanssen Pharmaceuticals, Inc.1999-06-26Not applicableUs
Ditropan XLtablet (extended-release)15 mgoralJanssen IncNot applicableNot applicableCanada
Ditropan XLtablet, extended release10 mg/1oralJanssen Pharmaceuticals, Inc.1999-06-26Not applicableUs
Ditropan XL -(10mg)tablet (extended-release)10 mgoralJanssen Inc2001-06-22Not applicableCanada
Ditropan XL -(5mg)tablet (extended-release)5 mgoralJanssen Inc2001-06-22Not applicableCanada
Dom-oxybutynin 5 Mg Tabletstablet5 mgoralDominion Pharmacal1999-12-16Not applicableCanada
Gelniquemetered-dose pump100 mgtopicalWatson Laboratories IncNot applicableNot applicableCanada
Gelniquegel28 mg/.92gtransdermalActavis Pharma, Inc.2012-04-02Not applicableUs
Gelniquegel100 mgtopicalActavis Specialty Pharmaceuticals Co2011-10-27Not applicableCanada
Gelniquegel100 mg/gtransdermalActavis Pharma, Inc.2009-05-15Not applicableUs
Gelniquegel100 mg/gtransdermalPhysicians Total Care, Inc.2010-09-15Not applicableUs
Mylan-oxybutynintablet5 mgoralMylan Pharmaceuticals Ulc1997-04-242016-06-28Canada
Ntp-oxybutynintablet5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-oxybutynsyrup1 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-oxybutyn - Tab 5mgtablet5 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Oxybutyn - 5mgtablet5 mgoralValeant Canada Lp/valeant Canada s.e.c.1996-10-312016-07-08Canada
Oxybutynintablet5 mgoralSanis Health Inc2010-05-12Not applicableCanada
Oxybutynin Chloridetablet, extended release15 mg/1oralMylan Pharmaceuticals Inc.2007-05-10Not applicableUs
Oxybutynin Chloridetablet, extended release15 mg/1oralPatriot Pharmaceuticals, LLC1999-06-26Not applicableUs
Oxybutynin Chloridetablet, extended release15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-05-10Not applicableUs
Oxybutynin Chloridetablet, extended release5 mg/1oralPatriot Pharmaceuticals, LLC1999-06-26Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralPatriot Pharmaceuticals, LLC1999-06-26Not applicableUs
Oxybutynine-5 - Tab 5mgtablet5 mgoralPro Doc Limitee1996-12-06Not applicableCanada
Oxytrolpatch3.9 mg/dtransdermalActavis Pharma, Inc.2003-02-26Not applicableUs
Oxytrolpatch36 mgtransdermalActavis Specialty Pharmaceuticals Co2004-08-12Not applicableCanada
Pat-oxybutynin Chloride ERtablet (extended-release)5 mgoralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-oxybutynin Chloride ERtablet (extended-release)10 mgoralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Pat-oxybutynin Chloride ERtablet (extended-release)15 mgoralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Penta-oxybutynin Chloride Tabletstablet5 mgoralPentapharm Ltd.Not applicableNot applicableCanada
PHL-oxybutynintablet2.5 mgoralPharmel Inc2004-12-02Not applicableCanada
PHL-oxybutyninsyrup1 mgoralPharmel Inc2004-12-06Not applicableCanada
PHL-oxybutynintablet5 mgoralPharmel Inc2002-05-29Not applicableCanada
PMS-oxybutyninsyrup1 mgoralPharmascience Inc1996-09-04Not applicableCanada
PMS-oxybutynintablet2.5 mgoralPharmascience Inc1999-11-22Not applicableCanada
PMS-oxybutynintablet5 mgoralPharmascience Inc1999-11-22Not applicableCanada
Riva-oxybutynintablet5 mgoralLaboratoire Riva Inc2000-05-052013-07-31Canada
Riva-oxybutynintablet5 mgoralLaboratoire Riva Inc2008-06-09Not applicableCanada
Teva-oxybutynintablet5 mgoralTeva Canada Limited1997-02-28Not applicableCanada
Uromaxtablet (extended-release)10 mgoralPurdue Pharma2006-05-152013-08-01Canada
Uromaxtablet (extended-release)15 mgoralPurdue Pharma2006-05-152013-08-01Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxybutyninsyrup1 mgoralApotex Inc1997-04-28Not applicableCanada
Apo-oxybutynin - Tab 5mgtablet5 mgoralApotex Inc1995-12-31Not applicableCanada
Oxybutynin Chloridetablet, film coated, extended release15 mg/1oralMylan Pharmaceuticals Inc.2006-11-10Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralCardinal Health2010-01-13Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Oxybutynin Chloridetablet, extended release5 mg/1oralTeva Pharmaceuticals USA Inc2007-05-11Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralCardinal Health2004-02-03Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralbryant ranch prepack2007-05-11Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release5 mg/1oralCardinal Health2010-07-282015-12-29Us
Oxybutynin Chloridetablet5 mg/1oralBlenheim Pharmacal, Inc.2013-10-02Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralMc Kesson Contract Packaging2011-12-23Not applicableUs
Oxybutynin Chloridetablet, extended release5 mg/1oralMarlex Pharmaceuticals Inc2016-02-01Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralREMEDYREPACK INC.2011-09-29Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralPhysicians Total Care, Inc.2006-12-11Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-20Not applicableUs
Oxybutynin Chloridetablet, extended release15 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-11-02Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralAidarex Pharmaceuticals LLC1997-10-31Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralREMEDYREPACK INC.2013-02-25Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralKAISER FOUNDATION HOSPITALS2015-10-14Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release5 mg/1oralCardinal Health2006-11-10Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralPd Rx Pharmaceuticals, Inc.1997-10-31Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Oxybutynin Chloridesolution5 mg/5mLoralQualitest Pharmaceuticals2004-12-28Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralCardinal Health1997-10-31Not applicableUs
Oxybutynin Chloridetablet, extended release5 mg/1oralAv Kare, Inc.2016-01-082016-03-18Us
Oxybutynin Chloridetablet5 mg/1oralBlenheim Pharmacal, Inc.2013-11-13Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralUnit Dose Services1990-09-30Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralTeva Pharmaceuticals USA Inc2007-05-11Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralCardinal Health1997-10-312016-02-25Us
Oxybutynin Chloridetablet, film coated, extended release5 mg/1oralMc Kesson Contract Packaging2011-10-12Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralMarlex Pharmaceuticals Inc2016-02-01Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralPliva Inc.1990-09-30Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralPhysicians Total Care, Inc.2006-12-12Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-20Not applicableUs
Oxybutynin Chloridetablet, extended release5 mg/1oralDispensing Solutions, Inc.2007-05-11Not applicableUs
Oxybutynin Chloridetablet, extended release15 mg/1oralREMEDYREPACK INC.2016-02-24Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-05-11Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralREMEDYREPACK INC.2013-05-29Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release5 mg/1oralMylan Pharmaceuticals Inc.2006-11-10Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralCardinal Health2013-05-20Not applicableUs
Oxybutynin Chloridetablet, extended release5 mg/1oralCarilion Materials Management2007-05-11Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralAphena Pharma Solutions Tennessee, Llc1997-10-31Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralQualitest Pharmaceuticals1997-10-31Not applicableUs
Oxybutynin Chloridesyrup5 mg/5mLoralMorton Grove Pharmaceuticals, Inc.1997-02-12Not applicableUs
Oxybutynin Chloridetablet, extended release5 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-11-02Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralAv Kare, Inc.2016-01-082016-03-18Us
Oxybutynin Chloridetablet5 mg/1oralRebel Distributors Corp.1997-10-31Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release5 mg/1oralMylan Institutional Inc.2006-11-27Not applicableUs
Oxybutynin Chloridetablet, extended release15 mg/1oralTeva Pharmaceuticals USA Inc2006-11-10Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralCardinal Health2011-05-20Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralMc Kesson Contract Packaging2011-09-19Not applicableUs
Oxybutynin Chloridetablet, extended release15 mg/1oralMarlex Pharmaceuticals Inc2016-02-01Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release5 mg/1oralPhysicians Total Care, Inc.2007-01-08Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralUpsher Smith Laboratories, Inc.2011-11-07Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralAmerican Health Packaging2010-01-13Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release5 mg/1oralAvera Mc Kennan Hospital2015-03-10Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralMylan Pharmaceuticals Inc.2006-11-10Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralCardinal Health2006-11-10Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralA S Medication Solutions1997-10-31Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralAphena Pharma Solutions Tennessee, Inc.2009-03-01Not applicableUs
Oxybutynin Chloridesyrup5 mg/5mLoralSilarx Pharmaceuticals, Inc2009-09-08Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-10-30Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralSt Marys Medical Park Pharmacy2013-05-16Not applicableUs
Oxybutynin Chloridetablet, extended release10 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-11-02Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralREMEDYREPACK INC.2013-04-05Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralMylan Institutional Inc.2006-11-27Not applicableUs
Oxybutynin Chloridesyrup5 mg/5mLoralPharmaceutical Associates, Inc.1998-12-18Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralCardinal Health2011-11-07Not applicableUs
Oxybutynin Chloridetablet, film coated, extended release10 mg/1oralCardinal Health2010-07-282015-12-29Us
Oxybutynin Chloridetablet, extended release15 mg/1oralPhysicians Total Care, Inc.2010-01-13Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralMajor Pharmaceuticals2004-02-03Not applicableUs
Oxybutynin Chloridetablet5 mg/1oralbryant ranch prepack1997-10-31Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release5 mg/1oralAmerican Health Packaging2012-01-10Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release5 mg/1oralAv Kare, Inc.2016-03-09Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-03-01Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release15 mg/1oralAv Pak2012-05-16Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release5 mg/1oralKremers Urban Pharmaceuticals Inc.2009-03-01Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release10 mg/1oralAv Kare, Inc.2016-03-09Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release10 mg/1oralAmerican Health Packaging2012-08-31Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release5 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-05-18Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release10 mg/1oralKremers Urban Pharmaceuticals Inc.2009-03-01Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release15 mg/1oralAv Kare, Inc.2016-03-09Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release5 mg/1oralAv Pak2012-05-17Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release15 mg/1oralKremers Urban Pharmaceuticals Inc.2009-03-01Not applicableUs
Oxybutynin Chloride Extended Releasetablet, extended release10 mg/1oralAv Pak2012-05-17Not applicableUs
Oxybutynin Chlorideextended Release Extended Releasetablet, extended release10 mg/1oralREMEDYREPACK INC.2013-09-19Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxytrol for Womenpatch3.9 mg/dtransdermalMSD Consumer Care, Inc.2013-08-19Not applicableUs
Oxytrol for Womenpatch3.9 mg/dtransdermalMSD Consumer Care, Inc.2013-08-19Not applicableUs
Oxytrol for Womenpatch3.9 mg/dtransdermalActavis Pharma, Inc.2016-01-01Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
DitropanNot Available
LenditroNot Available
Lyrinel XLNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxybutynin Chloride
Thumb
  • InChI Key: SWIJYDAEGSIQPZ-UHFFFAOYNA-N
  • Monoisotopic Mass: 393.207071602
  • Average Mass: 393.947
DBSALT000430
Categories
UNIIK9P6MC7092
CAS number5633-20-5
WeightAverage: 357.4864
Monoisotopic: 357.230393863
Chemical FormulaC22H31NO3
InChI KeyInChIKey=XIQVNETUBQGFHX-UHFFFAOYSA-N
InChI
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3
IUPAC Name
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate
SMILES
CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of overactive bladder.
PharmacodynamicsOxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.
Mechanism of actionOxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). By inhibiting particularily the M1 and M2 receptors of the bladder, detrusor activity is markedly decreased.
Related Articles
AbsorptionRapidly absorbed from gastrointestinal tract.
Volume of distribution
  • 193 L
Protein binding91%-93%
Metabolism

Hepatic, primarily by CYP3A4

SubstrateEnzymesProduct
Oxybutynin
N-desethyloxybutyninDetails
Route of eliminationOxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Half life12.4-13.2 hours
Clearance

Estimated to be 26L/h.

ToxicityLD50=1220 mg/kg (Orally in rats, Goldenthal)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9225
Blood Brain Barrier+0.9418
Caco-2 permeable+0.5989
P-glycoprotein substrateSubstrate0.7244
P-glycoprotein inhibitor IInhibitor0.6809
P-glycoprotein inhibitor IIInhibitor0.7244
Renal organic cation transporterNon-inhibitor0.558
CYP450 2C9 substrateNon-substrate0.812
CYP450 2D6 substrateNon-substrate0.7985
CYP450 3A4 substrateNon-substrate0.5213
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7137
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7038
BiodegradationNot ready biodegradable0.9878
Rat acute toxicity2.9059 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9548
hERG inhibition (predictor II)Inhibitor0.7337
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral5 mg
Tablet (extended-release)oral10 mg
Tablet (extended-release)oral5 mg
Geltopical100 mg
Geltransdermal100 mg/g
Geltransdermal28 mg/.92g
Metered-dose pumptopical100 mg
Solutionoral5 mg/5mL
Syruporal5 mg/5mL
Tabletoral5 mg/1
Tablet, extended releaseoral10 mg/1
Tablet, extended releaseoral15 mg/1
Tablet, extended releaseoral5 mg/1
Tablet, film coated, extended releaseoral10 mg/1
Tablet, film coated, extended releaseoral15 mg/1
Tablet, film coated, extended releaseoral5 mg/1
Patchtransdermal36 mg
Patchtransdermal3.9 mg/d
Syruporal1 mg
Tabletoral2.5 mg
Tablet (extended-release)oral15 mg
Prices
Unit descriptionCostUnit
Oxybutynin chloride powder54.47USD g
Oxytrol 3.9 mg/24hr Patches20.87USD patch
Oxytrol 3.9 mg/24hr patch20.06USD patch
Gelnique 10% gel sachets5.17USD g
Ditropan XL 15 mg 24 Hour tablet4.59USD tablet
Ditropan XL 10 mg 24 Hour tablet4.47USD tablet
Ditropan XL 5 mg 24 Hour tablet4.47USD tablet
Ditropan xl 15 mg tablet4.23USD tablet
Ditropan xl 10 mg tablet4.13USD tablet
Ditropan xl 5 mg tablet4.13USD tablet
Ditropan xl 5 mg tablet sa4.13USD tablet
Oxybutynin Chloride 15 mg 24 Hour tablet3.5USD tablet
Oxybutynin Chloride 10 mg 24 Hour tablet3.42USD tablet
Oxybutynin Chloride 5 mg 24 Hour tablet3.2USD tablet
Ditropan 5 mg tablet1.15USD tablet
Oxybutynin Chloride 5 mg tablet0.57USD tablet
Ditropan 5 mg/5ml Syrup0.26USD ml
Apo-Oxybutynin 5 mg Tablet0.26USD tablet
Mylan-Oxybutynin 5 mg Tablet0.26USD tablet
Novo-Oxybutynin 5 mg Tablet0.26USD tablet
Nu-Oxybutyn 5 mg Tablet0.26USD tablet
Pms-Oxybutynin 5 mg Tablet0.26USD tablet
Oxybutynin Chloride 5 mg/5ml Syrup0.21USD ml
Oxybutynin 5 mg tablet0.17USD tablet
Pms-Oxybutynin 2.5 mg Tablet0.14USD tablet
Pms-Oxybutynin 1 mg/ml Syrup0.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2218714 No2005-08-232016-05-08Canada
US5164190 No1993-12-112010-12-11Us
US5674895 Yes1995-11-222015-11-22Us
US5840754 Yes1995-11-222015-11-22Us
US5912268 Yes1995-11-222015-11-22Us
US6262115 Yes1995-11-222015-11-22Us
US6743441 No2000-04-262020-04-26Us
US7029694 No2000-04-262020-04-26Us
US7081249 No2000-04-262020-04-26Us
US7081250 No2000-04-262020-04-26Us
US7081251 No2000-04-262020-04-26Us
US7081252 No2000-04-262020-04-26Us
US7179483 No2000-04-262020-04-26Us
US7198801 No2002-06-252022-06-25Us
US8241662 No2000-04-262020-04-26Us
US8920392 No2011-03-262031-03-26Us
US9259388 No2009-11-062029-11-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point129-130 °CNot Available
logP4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP4.36ALOGPS
logP4.44ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)11.53ChemAxon
pKa (Strongest Basic)8.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity105.26 m3·mol-1ChemAxon
Polarizability41.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Masakatsu Shibasaki, “Method of producing oxybutynin and its derivatives.” U.S. Patent US20040006243, issued January 08, 2004.

US20040006243
General References
  1. Tupker RA, Harmsze AM, Deneer VH: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol. 2006 Aug;142(8):1065-6. [PubMed:16924061 ]
  2. Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med. 2006 Oct;64(9):326-8. [PubMed:17057269 ]
  3. Schollhammer M, Misery L: Treatment of hyperhidrosis with oxybutynin. Arch Dermatol. 2007 Apr;143(4):544-5. [PubMed:17438194 ]
External Links
ATC CodesG04BD04
AHFS Codes
  • 86:12.00
PDB EntriesNot Available
FDA labelDownload (144 KB)
MSDSDownload (73 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumAclidinium may increase the anticholinergic activities of Oxybutynin.
AclidiniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Ambenonium.
AmiodaroneThe serum concentration of Oxybutynin can be increased when it is combined with Amiodarone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Oxybutynin.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxybutynin.
AprepitantThe serum concentration of Oxybutynin can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Oxybutynin.
AtazanavirThe serum concentration of Oxybutynin can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Oxybutynin can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxybutynin.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxybutynin.
BenactyzineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxybutynin.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxybutynin.
BexaroteneThe serum concentration of Oxybutynin can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxybutynin.
BoceprevirThe serum concentration of Oxybutynin can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Oxybutynin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Oxybutynin can be decreased when it is combined with Bosentan.
Botulinum Toxin Type AOxybutynin may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BOxybutynin may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Butorphanol.
CarbamazepineThe metabolism of Oxybutynin can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Carfentanil.
CeritinibThe serum concentration of Oxybutynin can be increased when it is combined with Ceritinib.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Chlorphenoxamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Oxybutynin.
CimetropiumOxybutynin may increase the anticholinergic activities of Cimetropium.
ClarithromycinThe serum concentration of Oxybutynin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Oxybutynin can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Oxybutynin can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Oxybutynin can be increased when it is combined with Cobicistat.
CodeineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Codeine.
ConivaptanThe serum concentration of Oxybutynin can be increased when it is combined with Conivaptan.
CoumaphosThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Coumaphos.
CrizotinibThe metabolism of Oxybutynin can be decreased when combined with Crizotinib.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxybutynin.
CyclosporineThe metabolism of Oxybutynin can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxybutynin.
DarunavirThe serum concentration of Oxybutynin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Oxybutynin can be increased when it is combined with Dasatinib.
DecamethoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Decamethonium.
DeferasiroxThe serum concentration of Oxybutynin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Oxybutynin can be decreased when combined with Delavirdine.
DemecariumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxybutynin.
DexamethasoneThe serum concentration of Oxybutynin can be decreased when it is combined with Dexamethasone.
DexetimideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Oxybutynin can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydromorphine.
DiltiazemThe metabolism of Oxybutynin can be decreased when combined with Diltiazem.
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Donepezil.
DoxycyclineThe metabolism of Oxybutynin can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when Oxybutynin is combined with DPDPE.
DronabinolOxybutynin may increase the tachycardic activities of Dronabinol.
DronedaroneThe metabolism of Oxybutynin can be decreased when combined with Dronedarone.
EchothiophateThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Edrophonium.
EfavirenzThe serum concentration of Oxybutynin can be decreased when it is combined with Efavirenz.
EluxadolineOxybutynin may increase the constipating activities of Eluxadoline.
EnzalutamideThe serum concentration of Oxybutynin can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Oxybutynin can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Oxybutynin can be decreased when it is combined with Eslicarbazepine acetate.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxybutynin.
EthylmorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Etorphine.
EtravirineThe serum concentration of Oxybutynin can be decreased when it is combined with Etravirine.
FentanylThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Fentanyl.
FenthionThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Fenthion.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxybutynin.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxybutynin.
FluconazoleThe metabolism of Oxybutynin can be decreased when combined with Fluconazole.
FluvoxamineThe metabolism of Oxybutynin can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Oxybutynin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Oxybutynin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Oxybutynin can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Oxybutynin can be increased when it is combined with Fusidic Acid.
GalantamineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Oxybutynin.
Ginkgo bilobaThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Oxybutynin.
GlycopyrroniumOxybutynin may increase the anticholinergic activities of Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxybutynin.
HydrocodoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxybutynin.
HydromorphoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxybutynin.
IdelalisibThe serum concentration of Oxybutynin can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Oxybutynin can be decreased when combined with Imatinib.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Oxybutynin.
IndinavirThe serum concentration of Oxybutynin can be increased when it is combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxybutynin.
IsavuconazoniumThe metabolism of Oxybutynin can be decreased when combined with Isavuconazonium.
IsoflurophateThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Isoflurophate.
IsradipineThe metabolism of Oxybutynin can be decreased when combined with Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Oxybutynin.
ItraconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Oxybutynin can be increased when it is combined with Ivacaftor.
KetobemidoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ketobemidone.
KetoconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Ketoconazole.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Lofentanil.
LopinavirThe serum concentration of Oxybutynin can be increased when it is combined with Lopinavir.
LovastatinThe metabolism of Oxybutynin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Luliconazole.
MalathionThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxybutynin.
MefloquineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxybutynin.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.
MetixeneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Oxybutynin.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Oxybutynin.
MianserinMianserin may increase the anticholinergic activities of Oxybutynin.
MifepristoneThe metabolism of Oxybutynin can be decreased when combined with Mifepristone.
MinaprineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Mirabegron.
MitotaneThe serum concentration of Oxybutynin can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Oxybutynin can be decreased when it is combined with Modafinil.
MorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with N-butylscopolammonium bromide.
NabiloneOxybutynin may increase the tachycardic activities of Nabilone.
NafcillinThe serum concentration of Oxybutynin can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Nalbuphine.
NefazodoneThe serum concentration of Oxybutynin can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Oxybutynin can be increased when it is combined with Nelfinavir.
NeostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Neostigmine.
NetupitantThe serum concentration of Oxybutynin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Oxybutynin can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Oxybutynin can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Oxybutynin.
NormethadoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Oxybutynin is combined with NVA237.
OlaparibThe metabolism of Oxybutynin can be decreased when combined with Olaparib.
OpiumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Orphenadrine.
OsimertinibThe serum concentration of Oxybutynin can be increased when it is combined with Osimertinib.
OxycodoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxybutynin.
PalbociclibThe serum concentration of Oxybutynin can be increased when it is combined with Palbociclib.
PancuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pancuronium.
PentazocineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine.
PentobarbitalThe metabolism of Oxybutynin can be increased when combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentolinium.
PethidineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pethidine.
PhenobarbitalThe metabolism of Oxybutynin can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Oxybutynin can be increased when combined with Phenytoin.
PhysostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Physostigmine.
PipecuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxybutynin.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Oxybutynin.
PosaconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Posaconazole.
Potassium ChlorideOxybutynin may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Oxybutynin.
PrimidoneThe metabolism of Oxybutynin can be increased when combined with Primidone.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxybutynin.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxybutynin.
PyridostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Oxybutynin.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxybutynin.
RamosetronOxybutynin may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Oxybutynin can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Remifentanil.
RifabutinThe metabolism of Oxybutynin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Oxybutynin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Oxybutynin can be increased when combined with Rifapentine.
RitonavirThe serum concentration of Oxybutynin can be increased when it is combined with Ritonavir.
RivastigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Rivastigmine.
SaquinavirThe serum concentration of Oxybutynin can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybutynin.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Oxybutynin.
SildenafilThe metabolism of Oxybutynin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Oxybutynin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Oxybutynin can be increased when it is combined with Simeprevir.
SolifenacinThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Solifenacin.
St. John's WortThe serum concentration of Oxybutynin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Oxybutynin can be increased when it is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.
SulfisoxazoleThe metabolism of Oxybutynin can be decreased when combined with Sulfisoxazole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxybutynin.
TacrineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tapentadol.
TelaprevirThe serum concentration of Oxybutynin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Oxybutynin can be increased when it is combined with Telithromycin.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Oxybutynin.
TiclopidineThe metabolism of Oxybutynin can be decreased when combined with Ticlopidine.
TiotropiumOxybutynin may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Oxybutynin.
TocilizumabThe serum concentration of Oxybutynin can be decreased when it is combined with Tocilizumab.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxybutynin.
TopiramateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxybutynin.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxybutynin.
TrimethaphanThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxybutynin.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxybutynin.
TubocurarineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Oxybutynin.
UmeclidiniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Vecuronium.
VenlafaxineThe metabolism of Oxybutynin can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Oxybutynin can be decreased when combined with Verapamil.
VoriconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Voriconazole.
ZiprasidoneThe metabolism of Oxybutynin can be decreased when combined with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Baldwin CM, Keating GM: Transdermal oxybutynin. Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008. [PubMed:19275276 ]
  4. Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13. [PubMed:19446545 ]
  5. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  6. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678 ]
  7. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9. [PubMed:16406943 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Dmochowski R: Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. Drug Saf. 2005;28(7):583-600. [PubMed:15963006 ]
  2. Nelson CP, Nahorski SR, Challiss RA: Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2006 Jan;316(1):279-88. Epub 2005 Sep 27. [PubMed:16188951 ]
  3. Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13. [PubMed:19446545 ]
  4. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  5. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  4. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678 ]
  5. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9. [PubMed:16406943 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Yaich M, Popon M, Medard Y, Aigrain EJ: In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics. 1998 Oct;8(5):449-51. [PubMed:9825837 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 03:02